Instil Bio
TILClinical Pipeline
No assets found matching the corporate key (TIL)
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
— — — —
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($6.16M) ($5.89M) ($27.22M) ($5.35M)
Operating Income / (Loss)
($23.44M) ($15.02M) ($78.58M) ($7.01M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
($1.58M) ($1.58M) ($5.83M) ($1.55M)
Other Non-Operating Income / (Expense)
$0.34M ($0.12M) $0.21M ($0.18M)
Income Tax Provision / (Benefit)
— — $0.00M —
NET INCOME / (NET LOSS)
($21.39M) ($13.59M) ($71.37M) ($4.20M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$7.7M$5.8M$6.6M$5.0M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$7.7M$5.8M$6.6M$5.0M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$3.3M$4.2M$3.0M$1.5M
Total Current Assets
$207.4M$196.3M$191.4M$188.3M
Property, Plant and Equipment, Net
$0.1M$0.1M$0.1M$0.1M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$231.0M$211.8M$203.5M$200.4M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$0.5M$0.9M$0.8M$0.8M
Accrued Expenses & Clinical Liabilities
$1.4M$2.1M$2.5M$2.3M
Total Current Liabilities
$13.9M$5.7M$4.8M$4.7M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$85.5M$85.6M$84.8M$85.0M
Total Liabilities Block
$99.3M$91.3M$89.7M$89.7M
Total Stockholders' Equity
$131.7M$120.4M$113.9M$110.7M
TOTAL LIABILITIES & EQUITY
$231.0M$211.8M$203.5M$200.4M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
14.97x 34.45x 39.53x 39.87x
R&D Expenditure Flow
$12.1M$21.2M$24.7M$0.7M
Net Income / (Loss)
($21.39M) ($13.59M) ($71.37M) ($4.20M)
Depreciation & Amortization
$0.51M $0.52M $0.53M $0.01M
Stock-Based Compensation
$5.32M $7.09M $8.69M $0.98M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
($5.83M) ($4.93M) ($6.12M) ($1.53M)
Change in Payables & Clinical Accruals
($0.14M) $0.26M $0.12M $0.02M
Other Operating Source / (Use) Changes
$2.55M ($18.90M) $31.52M $3.38M
Net Cash from Operating Activities
($18.99M) ($29.54M) ($36.62M) ($1.34M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
— — — —
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
$85.70M $110.70M $135.90M $22.00M
Net Cash from Investing Activities
$9.21M $17.66M $25.48M ($0.32M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
$6.61M $6.61M $6.61M —
Net Cash from Financing Activities
$6.91M $7.29M $7.29M $0.00M
NET CONSOLIDATED CHANGE IN CASH
— — — —
Clinical Trials Registry
No active clinical trials detected in data stream.